Stop FDA Delays: Structured Product Labeling Translation
For FDA submissions, translate only the human-readable content-of-labeling. Prepare the file using a validated AI+HUMAN hybrid translation workflow with subject-matter expert (SME) sign-off, keep every coded field (NDC, UNII, LOINC) untouched, and run pre-submission validation against the FDA’s SPL Implementation Guide before you file.
TL;DR:
Translating only the content-of-labeling sections and keeping code fields locked prevents validation rejections caused by data inconsistencies and incorrect formatting.
A strict workflow that includes asset integration, AI-constrained translation, SME review, QA, and validation is essential for compliance and error prevention.
Confirm cross-document consistency of codes like NDC, UNII, and DUNS, and avoid reusing or editing codes after formulation changes to prevent FDA rejection.
Regularly automate and verify validation scripts both before and after SME review to catch last-minute errors, image placement issues, and code mismatches.
Choosing a vendor with ISO certifications, SME access, and clear audit trails ensures regulatory compliance and efficient submission of FDA filings.
Table of Contents
What Is Structured Product Labeling and What Actually Gets Translated?
Structured Product Labeling (SPL) is the HL7-approved XML document format the FDA requires for drug establishment registration, drug listing, and content-of-labeling submissions. It’s built on the Clinical Document Architecture and HL7’s Reference Information Model, which means every SPL file is really two documents stitched together: a governed data layer and a linguistic layer. Only the linguistic layer gets translated.
The content-of-labeling sections (indications and usage, dosage and administration, warnings, contraindications) are free text meant for prescribers, pharmacists, and patients. Those sections get translated. Everything else in the file is machine-readable data that identifies the product to FDA systems, and it must stay code-accurate:
NDC (National Drug Code) identifiers: never retranslate, reformat, or renumber.
UNII codes for active ingredients: fixed values, not language-dependent.
LOINC document type codes (for example 51725-0 for prescription drug labeling, 34391-3 for a package insert) that determine which sections are required and how the file validates.
Establishment registration numbers and labeler codes tied to DUNS records.
Mixing up these two layers, translating a code field or leaving a data element in the source language, is one of the most common ways an otherwise well-translated SPL file gets kicked back.
What Is the Correct Workflow for Translating and Validating SPL?
A compliance-first SPL translation project follows a fixed sequence. Skipping a step, especially SME review, is how safety language slips through with subtle but material errors.
Asset integration. Ingest the client’s existing Translation Memory ™ and Term Base (TB) before any generation starts. Lock all code fields (NDC, UNII, LOINC, DUNS) so they cannot be edited downstream, and build a mapping table that ties each structured field to its corresponding human-readable text.
Constrained generation. Run the content-of-labeling text through an AI system constrained by the locked terminology and the client’s style guide. Flag every generated passage for review rather than treating it as final. Coded and identifier fields are excluded from this step entirely.
SME review. A certified medical or regulatory linguist checks indications, contraindications, dosing language, and warnings for clinical accuracy and regulatory tone, not just fluency. This is where dosage phrasing, negation (“not indicated for” versus a weaker equivalent), and route-of-administration nuance get caught.
QA and automated validation. Quality assurance aligned to ISO 17100 and ISO 18587 runs alongside automated checks against the FDA’s numbered SPL validation procedures and the LOINC document-type rules that govern required sections.
Pre-submission packaging. Confirm version control, maintain an audit trail of every edit, verify image files are placed as JPEGs in the correct SPL elements, and generate a final validation report to include in the submission packet.
Pro Tip: Run the FDA validation script twice, once right after SME review and once immediately before packaging. A last-minute image swap or a labeler code correction can silently break a field that validated cleanly an hour earlier.
How Do You Choose a Vendor or Justify an Internal Process?
Selecting a translation approach for SPL is a regulated decision, not a procurement exercise. Weigh these criteria before signing off:
Certifications and process controls. Look for ISO 17100 and ISO 18587 alignment for translation and post-editing quality, plus ISO 27001 and ISO 42001 for information security and AI governance. If protected health information is anywhere in scope, HIPAA alignment is not optional.
Auditability. The vendor should produce version histories, change logs, and a pre-submission validation report that references the actual numbered procedures in the FDA Implementation Guide, not a generic “quality passed” statement.
SME access. Confirm the vendor has medical and regulatory linguists available for sign-off and for resolving disputes over ambiguous safety language, not just general-purpose translators.
Data sovereignty. Where the file touches PHI or unpublished regulatory content, contractual guarantees on hosting location and processing controls matter as much as translation quality.
Operational fit. Check turnaround for urgent label corrections, capacity for simultaneous multi-language launches, and whether the vendor can ingest your existing TM and TB rather than starting terminology from scratch.
Cross-border contracting for large multi-market localization programs also raises payment and data-transfer questions worth clarifying in the vendor agreement, an area covered in general terms by resources like this international compliance guide.
What Do a Localized Labeling Section and an NDC Change Actually Look Like?
Translating “Indications and Usage.” The English source text is fully replaced with the target-language equivalent, reviewed by an SME for clinical accuracy. The surrounding XML tags, the LOINC document type code, and any cross-references to other sections stay exactly as they were. Before filing, run the validation checks tied to required-section presence and confirm the translated text renders correctly under the FDA’s SPL stylesheet.
A formulation change that requires a new NDC. When active ingredient, strength, or dosage form changes, FDA rules require a new NDC rather than an edit to the existing product code. Translators do not touch the old NDC entry. Regulatory affairs issues the new code, a new product block is created, and only that new block’s labeling text goes through the translation workflow. Verify labeler code consistency and DUNS matching across every related document before submission.
What Causes SPL Rejections, and How Do You Prevent Them?
Most translated SPL rejections trace back to a handful of repeat offenders, and nearly all of them are preventable with the right checks built into the workflow.
Cross-document inconsistency. A labeler code or DUNS number that doesn’t match across related files is a frequent cause of rejection, independent of any XML schema error. Mitigation: automate cross-file reconciliation and run a DUNS consistency check before packaging.
Incorrect or reused NDC values. Reusing an NDC after a formulation change, or formatting it incorrectly, triggers a hard validation failure. Mitigation: run automated NDC format scripts and enforce a policy requiring a new NDC whenever ingredient, strength, or form changes.
Accidental translation of coded fields. A translator or an unconstrained AI pass can overwrite a code value. Mitigation: lock code fields at the term-base level and use schema-aware QA that flags any edit to a structured element.
Image placement failures. Incorrectly placed or non-JPEG images in labeling elements break rendering. Mitigation: verify image placement against the SPL schema and test rendering with FDA’s own stylesheet before submission.
Pro Tip: Automate the validation procedure run itself and attach the resulting report directly to the submission packet. A reviewer who can see the procedure numbers you checked, not just a pass/fail summary, moves your file through review faster.
Where Does AD VERBUM Fit Into an SPL Translation Project?
This vendor is built for regulated, high-stakes documentation work. Its translation engine generates content-of-labeling text constrained by the client’s existing terminology, then routes it through subject-matter expert review before finalization. This AI+HUMAN hybrid translation model follows the structured workflow described above.
Relevant capabilities for an SPL engagement include:
Infrastructure supporting data sovereignty requirements for regulated content and PHI.
Access to subject-matter expert linguists, including medical professionals, for SME sign-off on clinical language.
Translation Memory and Term Base integration to carry locked code-field terminology through every language pass.
QA aligned to ISO 17100 and ISO 18587, supported by security and AI-governance certifications.
Industry pilots confirm the direction: AI accelerates drafting and translation for SPL, but consensus across the sector is that human SME review stays mandatory for safety-critical labeling. AD VERBUM is a reasonable fit when the project needs an audit trail, documented SME sign-off, and ISO-aligned QA behind every translated section headed for an FDA filing.
What Should You Do Before You File?
Run through this before an SPL translation leaves your desk:
Run automated validation against the FDA Implementation Guide’s numbered procedures, not a generic spell-check pass.
Lock every coded field and confirm NDC, UNII, and LOINC values weren’t touched during translation.
Get documented SME sign-off and complete ISO-aligned QA before the file moves to packaging.
Generate an audit-ready pre-submission validation report and attach it to the submission packet.
The one-line version: translate the content-of-labeling, never the codes, run it through an AI+HUMAN hybrid workflow with SME sign-off, and validate against the FDA’s own procedures before you file. If you need a compliance-first vendor to run that process, AD VERBUM is built for it.
Why Most SPL Translation Advice Skips the Hard Part
Most guidance on SPL translation treats it as a linguistic problem with a regulatory footnote attached. That gets the priority backwards. The translation quality of an indications section rarely sinks an FDA filing. A mismatched DUNS number or a reused NDC does, and those are data governance failures, not language failures.
The overlooked nuance is that SPL punishes teams for treating it as one document when it’s structurally two: a governed data layer and a linguistic layer bolted together in the same XML file. Vendors and internal teams that succeed treat these as separate workflows with separate owners, translators handle prose, regulatory affairs owns the codes, and nobody crosses that line without a sign-off. Teams that fail tend to let one generalist handle both, assuming fluency in the source language covers fluency in HL7’s data model. It doesn’t.
If there’s one thing to prioritize above translation vendor selection, it’s building the field-locking and validation-automation habit first. A mediocre translation with clean code fields and a passing validation report gets through review. A beautiful translation with a mismatched labeler code does not.
— Eric Brown
Get Compliance-First SPL Translation Support From AD VERBUM
AD VERBUM’s advantage for SPL work isn’t speed for its own sake, it’s speed with the audit trail already built in. Where a generalist translation vendor hands you finished text and leaves the validation risk on your desk, AD VERBUM’s AI+HUMAN hybrid translation workflow pairs the LangOps System with certified SME linguists and ISO 17100/18587-aligned QA, so the sign-off documentation and pre-submission checks come standard, not as an add-on you have to request.
That matters most for regulatory teams managing multiple label updates across languages under a filing deadline, where a rejected SPL file costs weeks, not days. AD VERBUM’s EU-hosted infrastructure and ISO 27001/42001 security posture also address the data sovereignty questions that come up whenever PHI or unpublished regulatory content moves through a translation pipeline. If your team is preparing an SPL submission and needs a vendor that treats code-field governance and SME review as non-negotiable steps, not optional extras, visit AD VERBUM’s services page to request a quote for your next SPL translation project.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
Recommended